HSTCL Study for Patients with Inflammatory Bowel Disease

Background

Hepatosplenic T-Cell Lymphoma (HSTCL) is a rare type of T-cell (a type of white blood cell or lymphocyte) lymphoma. It is an aggressive cancer affecting the liver, spleen, and sometimes the bone marrow. In most cases, HSTCL is fatal. There are documented cases of HSTCL in patients using anti-TNF agents, azathioprine, or 6-mercaptopurine. Most of these cases occurred in patients with ulcerative colitis or Crohn’s Disease, which are types of inflammatory bowel disease. However, patients with psoriasis or rheumatoid arthritis have also developed HSTCL.

Objective

In order to learn more about HSTCL, Janssen is conducting a study to collect samples from patients with inflammatory bowel disease who have, or have had a confirmed diagnosis of HSTCL. Samples obtained will be stored for future testing to identify factors that may predict the risk of developing HSTCL. In addition, demographic and clinical patient information will be collected.

There is no study-related therapeutic intervention and this study will not restrict or introduce any therapeutic interventions, including medications. All patients will continue to be managed by their personal physicians.

If you or anyone you know with inflammatory bowel disease has developed HSTCL, please consider contacting Janssen for further information on this study. Please note that the study is also accepting stored samples that may exist from patients who are deceased.

For Additional Information:

Contact:

Janssen Medical Information

1-800-JANSSEN (1-800-526-7736)
Monday-Friday 9:00AM-8:00PM EST
Saturday and Sunday 9:00AM-5:00PM EST